Both the CTLA-4 pathway and regulatory T cells (Treg) are essential for the control of immune homeostasis. Their therapeutic relevance is highlighted by the increasing use of anti-CTLA-4 antibody in tumor therapy and the development of Treg cell transfer strategies for use in autoimmunity and transplantation settings. The CTLA-4 pathway first came to the attention of the immunological community in 1995 with the discovery that mice deficient in Ctla-4 suffered a fatal lymphoproliferative syndrome. Eight years later, mice lacking the critical Treg transcription factor Foxp3 were shown to exhibit a remarkably similar phenotype. Much of the debate since has centered on the question of whether Treg suppressive function requires CTLA-4. The finding that it does in some settings but not in others has provoked controversy and inevitable polarization of opinion. In this article, I suggest that CTLA-4 and Treg represent complementary and largely overlapping mechanisms of immune tolerance. I argue that Treg commonly use CTLA-4 to effect suppression, however CTLA-4 can also function in the non-Treg compartment while Treg can invoke CTLA-4-independent mechanisms of suppression. The notion that Foxp3 and CTLA-4 direct independent programs of immune regulation, which in practice overlap to a significant extent, will hopefully help move us towards a better appreciation of the underlying biology and therapeutic significance of these pathways.
found to exhibit dysregulated T cell immunity resulting in tissue infiltration and death around 3wk of age [3,4]. Pathology resulted from the unchecked expansion of T cells possessing a diverse and unbiased TCR repertoire [14] and exhibiting reactivity against self tissues. Disease appeared to be driven by the CD4 compartment un inhibited expression of cytokines such as IL-2.

3. Control of T cell responses by Treg

3.1. Treg as essential immune regulators

The notion that the peripheral immune compartment is not entirely self tolerant but is policed by cells with regulatory activity has now been firmly incorporated into mainstream immunology. Early work by the Powrie, Sakaguchi and Shevach groups showed that cells with immunoregulatory activity could be identified on the basis of their CD45 isofrom usage [36], or their expression of CD38 [37] or CD25 [38–41]. It is now well established that Treg are essential for the maintenance of tolerance to self-tissues (particularly those that announce their presence via secretory function) as well as regulating responses to environmental antigens, tumor antigens and infectious agents [42–44]. Treg have also been implicated in maintaining tolerance to the fetus during pregnancy [45–48] and the role of peripherally induced Treg may be particularly significant in this context [49]. Multiple suppressive mechanisms can be invoked by Treg [50,51] permitting them to control a broad range of target cell populations in different contexts.

3.2. Identification of the Treg transcription factor Foxp3

A key landmark in the Treg field was the identification of the transcription factor Foxp3 that plays a central role in directing the regulatory program (see Fig. 1). This discovery arose from a sequencing project [52] to determine the causal mutation in the scurfy mouse, an animal presenting with a severe lymphoproliferative syndrome [53]. The Foxp3 gene was pinpointed as the culprit, and it was shown that a frameshift mutation in scurfy mice resulted in a product lacking the carboxy-terminal forkhead domain [52]. Crucially, the Sakaguchi [54], Rudensky [55] and Ramsdell [56] groups then made the link between the CD25+ Treg population and the immune-regulatory function of the Foxp3 gene. It was demonstrated that Foxp3 expression was essentially confined to CD4+CD25+ cells and was responsible for the regulatory activity of this subset. Accordingly, adoptive transfer of CD4+CD25+ T cells from wildtype mice could rescue the lymphoproliferative syndrome in scurfy mice [55] and retroviral expression of Foxp3 in CD25− T cells was shown to endow them with regulatory function [54,55]. Similarly, transgenic expression of Foxp3 permitted CD25− T cells, and even CD8 T cells to acquire regulatory activity [56]. Consistent with the large body of evidence obtained in mouse models, mutations in the Foxp3 gene in humans are associated with defective immune regulation, manifesting as a syndrome that has been termed immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) [57,58]. It is now well established that although some features of the Treg program emerge prior to [59] or independently of [60] Foxp3 expression, Foxp3 is nonetheless critical for enforcing the regulatory phenotype. In thymic-derived Treg, Foxp3 is turned on in developing thymocytes with the majority of Foxp3+ cells being CD4+CD8− cells and residing in the medulla [61]. The strength of TCR signaling “translated” by induction of Nr4a nuclear receptors [62] and CD28 co-stimulation [63] both contribute to upregulation of Foxp3 intrathymically. However, expression of the “C-terminal proline motif “PYAP” (residues 187–190) that associates with Lck, Fyn and Grb2. Strikingly this approach revealed that disease mapped to the status of the CD28 C-terminal proline motif. Cita4−/− mice expressing CD28 molecules with two single point mutations in this motif remained completely healthy, whereas mutations in other regions of the CD28 cytoplasmic domain did not interrupt pathology. Collectively these studies provide strong evidence that the role of CTLA-4 is to regulate CD28-dependent T cell activation.

2.3. CTLA-4 regulates the CD28 pathway

Several lines of evidence support the view that the biological function of CTLA-4 is to control CD28 signaling. Blocking CD80 and CD86 with CTLA-4-Ig (thereby abrogating CD28 signaling) is known to inhibit disease in Cita4−/− mice [30,31]. Similarly mice that lack CD80 and CD86 as well as CTLA-4 (i.e. triple knockout mice) show no signs of the immune dysregulation associated with CTLA-4 deficiency [32,33]. The requirement for CD80/CD86 to drive disease in Cita4−/− mice reflects their engagement of CD28, since mice lacking both CD28 and CTLA-4 have no evidence of spontaneous T cell activation and do not develop pathology [34]. An intriguing study from the Singer laboratory delved deeper into this issue by probing which regions of the CD80 cytoplasmic domain were required for pathology in Cita4−/− mice [35]. The candidate regions under investigation were the “YMNM” motif (residues 170–173) known to bind phosphoinositide 3-kinase (PI3K), Grb2 and Gads; the “N-terminal proline” motif “PRRP” (residues 175–178) that binds Itk; and the ICOS locus have long been associated with autoimmunity [20–22] and further variation within the same gene cluster (CD28, ICOS) is consistent with the above observations, polymorphisms in the Cita4 locus have long been associated with autoimmunity [16–18] and could even induce autoimmune manifestations in normal mice including gastritis, oophoritis, and mild sialoadenitis [19].

Consistent with the above observations, polymorphisms in the Cita4 locus have long been associated with autoimmunity [20–22] and further variation within the same gene cluster (CD28, ICOS) is likely to contribute to the net phenotype imparted by this region [23]. Several isoforms of CTLA-4 exist [21,24–29] and their relative expression levels may also influence CTLA-4-dependent immune regulation.
Foxp3 in the thymus alone is insufficient to prevent disease in scurfy mice [64] and ablation of Foxp3-expressing cells in adult mice (by exploiting Foxp3-driven diphtheria receptor expression) causes fatal autoimmunity [2], consistent with a requirement for continuous Foxp3 expression for Treg function. Treg preferentially accumulate in lymph nodes draining the tissues that express their cognate self-antigen [65] and as a consequence the Treg repertoire can vary considerably between different anatomical locations [66].

3.3. What does Foxp3 do?

The question of precisely what Foxp3 does to elicit the regulatory program has proved harder than expected to tease out. Analysis of Foxp3-bound genes has uncovered numerous targets [67,68], however none fulfilled the “holy grail” criterion of providing a convincing molecular explanation for Treg function. Indeed the Foxp3 target genes appeared to comprise only around 6% of the Foxp3-dependent genetic program [67]. Recent analysis of Foxp3-bound genes has uncovered numerous targets [67,68], however none fulfilled the “holy grail” criterion of providing a convincing molecular explanation for Treg function. Indeed the Foxp3 target genes appeared to comprise only around 6% of the Foxp3-dependent genetic program [67]. Recent analysis of Foxp3-bound genes has uncovered numerous targets, although these included some of the Foxp3-interacting proteins that had previously been described (e.g. NFAT [70] Runx [71]), other known binding-partners (e.g. Irf4 [72], Hif1α [73]) were not identified in this approach. This hints that contextual cues (e.g. activation stimuli, hypoxia) may influence the composition of the proteins recruited to the Foxp3 complex [69]. Thus the transcriptional program directed by Foxp3 is likely to depend on the cellular environment in which it is expressed since this will dictate its interactions with different co-factors. As a basic principle, this may explain why historically not all attempts to confer regulatory function by Foxp3 transduction have been successful [74,75] and why B cells from Foxp3 transgenic mice fail to exhibit suppressive function [56].

Intriguingly, a distinct subset of Foxp3-binding transcription factors appears to play a particularly important role in supporting its function. Fu and colleagues identified a “quintet” of transcription factors (Eos, Irf4, GATA-1, Lef1 and Satb1) that appear to reinforce the regulatory program by promoting Foxp3 occupancy of target sites and enhancing its transcriptional activity [76]. In human Treg, a novel Foxp3 interacting protein termed FIK (Foxp3-interacting KRAB domain-containing protein) has recently been identified that serves to couple Foxp3 with the chromatin-remodeling scaffold protein KAP1 [77]. The interaction of Foxp3 with FIK and KAP1 was found to be particularly important for its ability to down-regulate genes such as IL-2 and IFNγ while it was not required for Foxp3-dependent upregulation of CTLA-4 and CD25. Collectively these studies suggest that molecular control of Foxp3-dependent regulation is highly complex involving large numbers of interacting cofactors and the capacity to integrate multiple contextual cues.

4. Intersection between Treg- and CTLA-4-mediated tolerance

4.1. Early convergence of the Treg and CTLA-4 fields

The similarity between the phenotype of CTLA-4-deficient and Foxp3-deficient mice sparked immediate interest in whether these two genes might function in a common pathway. In other words, could the CTLA-4 pathway explain the regulatory function of Foxp3+ Treg? Early indications of the overlap between CTLA-4 and Treg came from careful analysis of the regulation of CTLA-4 expression during T cell responses to peptide in vivo [78]. In this study Metzler and colleagues identified a small population of CTLA-4+ cells in mice that had not been immunized with specific peptide. They characterized this population as CD25+ and CD45RBlow and speculated that CTLA-4 expression might represent a “common denominator” underpinning the regulatory function of both CD25+ and cells and CD45RBlow cells [78].

Potential links between the Foxp3 and CTLA-4 programs were also probed by testing whether CTLA-4 was absent from scurfy mice or whether CTLA-4-deficient animals lacked Treg. In both cases, quite the opposite was observed; scurfy [52] or Foxp3-deficient [55] mice expressed at least as much CTLA-4, if not more, than their wildtype counterparts and CTLA-4-deficient mice actually harbored an augmented Treg population [79–81]. Thus, despite the tantalizing similarity between the phenotypes of mice lacking either gene, Foxp3 was not required for CTLA-4 induction and nor was CTLA-4 required for expression of Foxp3.

4.2. Foxp3−/− and CTLA-4−/− phenotypes are corrected in the presence of wildtype cells

Consistent with the ability of Foxp3+ cells to elicit dominant regulation, the presence of wildtype cells has been shown to abolish the scuffy phenotype in mixed bone marrow chimeras [82,83]. In fact injection of 106 CD4+CD25+ cells was able to prevent disease in Rag-deficient recipients of scurfy bone marrow [84] while transfer of 4 × 106 wildtype CD4+CD25+ cells directly into 1–2 day old scurfy mice can restore immune homeostasis [55]. As expected, bone marrow cells from animals impaired in their capacity to generate Treg, as a result of Foxo1/Foxo3 deficiency, are unable to prevent the scurfy phenotype in mixed chimeras [83].

The correction of Treg deficiency (i.e. the scuffy phenotype) by the presence of wildtype cells could be viewed as entirely predictable, given the acknowledged role of this subset in eliciting cell-extrinsic regulation. Far more surprising was the observation that CTLA-4 deficiency could be compensated for in exactly the same way, namely by the mixing of CTLA-4−/− bone marrow with wildtype bone marrow in chimeric mice (see Table 1). This observation was reported by Bachmann and colleagues who found that rag−/−/C0 mice reconstituted with CTLA-4−/−/C0 bone marrow alone died roughly 10 weeks later whereas those that also received wildtype bone marrow remained completely healthy [85]. Even more striking was the finding that the CTLA-4−/− T cells in such mixed chimeras showed no signs of activation, suggesting that CTLA-4 expression on one T cell was able to control the activation status of another T cell. Given that an inhibitory signal delivered via the CTLA-4 receptor was then the favored model for CTLA-4 function cell-extrinsically; i.e. T cells do not themselves need to express CTLA-4 to feel its force.

Table 1

|                      | Foxp3-deficient bone marrow | CTLA-4−/− bone marrow |
|----------------------|----------------------------|-----------------------|
| Alone                | Sick [82,83]                | Sick [82,85,87,111]   |
| Plus wildtype bone marrow | Healthy [82,83]            | Healthy [33,82,85–88] |
| Plus wildtype CD4+CD25+ cells | Healthy [84]             | Healthy [87,111]     |

The Foxp3−/− and CTLA-4−/− phenotypes can be corrected by the presence of wildtype cells. The effect of adoptive transfer of the indicated bone marrow into Rag-deficient recipients, alone or with additional cells, is shown (in terms of whether recipients became sick or remained healthy). Note: Depending on the study, “Foxp3 deficient bone marrow” refers to bone marrow from mice lacking the Foxp3 gene or bone marrow from scurvy mice that have a frameshift mutation in the Foxp3 gene.
Given the ability of both CTLA-4+ cells and Foxp3+ cells to elicit dominant regulation in bone marrow chimeric mice, the Bluestone group sought to determine whether these two genes had to be expressed in the same cell for regulation to occur [82]. To this end, bone marrow from scurfy mice or CTLA-4−/− mice (also lacking CD80 and CD86) was injected alone or as a 1:1 mix into rag−/− recipients. For the first 50 days after transfer, the survival curves were indistinguishable between the 3 groups, with around 50% mortality during this period. However, subsequently a fraction of the animals receiving the mixed bone marrow showed a delayed decline, even though they all eventually died. These data hint at the ability of either Foxp3 or CTLA-4 (or both) to function independently of one another. However the fact that all mice receiving the mix of scurfy and CTLA-4−/− bone marrow died indicates that CTLA-4 and Foxp3 must be co-expressed in the same cell for efficient immune regulation to ensue. These data nicely complement the observation that transgenic overexpression of Foxp3 can delay lethality in CTLA-4−/− mice, but can only provide a temporary reprieve [56]. Together the data strongly suggest that effective immune regulation requires at least a subset of cells to co-express Foxp3 and CTLA-4.

4.3. Role for CTLA-4 in Treg function

Studies by the Powrie [89] and Sakaguchi [19] groups were the first to provide direct evidence that the CTLA-4 pathway could be used to elicit Treg suppression. However, the field was fraught with conflicting data. Early work from the Shevach group suggested that anti-CTLA-4 antibody failed to reverse Treg suppression in vitro [41], and others generated similar data [90]. A subsequent follow-up analysis by the Shevach group concluded that different preparations of anti-CTLA-4 antibody showed significant variation in their capacity to inhibit suppression [91]. In addition, interpretation of the results was complicated by the ability of such antibodies to augment conventional T cell proliferation [91], raising the possibility that the treatment increased conventional T cell (Tconv) proliferation rather than altering the extent of Treg suppression. This caveat was elegantly side-stepped in two other studies where anti-CTLA-4 Fab fragments were demonstrated to abolish suppression even in settings in which the conventional T cells were derived from CTLA-4−/− mice (and therefore could not be the target of the anti-CTLA-4 antibody) [19,31].

At face value, the above findings would appear to conclusively demonstrate a critical role for CTLA-4 in Treg function in vitro. However, this is not the whole story since testing this hypothesis by gene-deficiency has continued to produce conflicting results. Some studies show clearly that CTLA-4 deficiency abrogates Treg function in in vitro assays [81,88]. On the other hand, numerous reports have demonstrated that Treg from CTLA-4−/− mice retain suppressive function in vitro [31,79,92–94]. In some cases the CTLA-4−/− Treg suppress marginally less efficiently than wildtype Treg [79,93] mirroring the early observation that CTLA-4−/− Treg showed ~50% suppression compared to the ~95% suppression elicited by their wildtype counterparts [19]. Interestingly, Tang and colleagues found that even though CTLA-4−/− Treg were capable of suppression, the function of wildtype Treg was abrogated by anti-CTLA-4 antibody. This suggests that wildtype Treg use CTLA-4 to suppress but that compensatory mechanisms might develop in animals genetically deficient in the CTLA-4 pathway. The potential for gene-deficient animals to invoke compensatory pathways is elegantly illustrated by the observation that dual deficiency in IL-10 and IL-35 results in a striking compensatory increase in TRAIL (tnf10) expression and increased reliance on the TRAIL pathway for in vitro suppression [95].

The discrepancies in CTLA-4 dependence of Treg suppression in vitro hold true in human as well as mouse. For example in some studies anti-CTLA-4 antibody failed to interrupt human Treg suppression [96], while in others suppression was found to be largely CTLA-4 dependent with a minor contribution from TGFβ [97]. Supporting a role for CTLA-4 on Treg, depletion of CD25+ cells was shown to abrogate the ability of anti-CTLA-4 antibody to augment the proliferation of human T cells [98]. Thus, just like the analysis of mouse Treg, evidence both for and against a role for CTLA-4 in Treg function has been obtained in vitro using human cells. The most likely explanation for these conflicting data is that variation in assay conditions (APC type, strength of TCR stimulus... etc) has a profound impact on the CTLA-4 dependency of suppression. In at least two studies, CTLA-4−/− Treg were demonstrated to work in vitro yet lacked suppressive capacity in vivo [79,94] emphasizing the potential limitations of in vitro suppressive assays; ultimately their reductionist nature might permit redundant mechanisms to compensate for CTLA-4 deficiency more readily than in more complex in vivo situations.

There is now overwhelming evidence to support a role for CTLA-4 in the function of Treg in vivo settings. A selection of this evidence is presented in Table 2. The emergence of cell-extrinsic models of CTLA-4 function [11–13] has provided a mechanistic basis for its role in the Treg compartment and a conceptual framework for interpretation of the original bone marrow chimera experiments. A key piece in this puzzle has been provided by the demonstration that CTLA-4 can physically remove its ligands from antigen presenting cells by a process of trans-endocytosis, affording a mechanism for Treg to regulate CD28 stimulation of other T cells [99].

Experimental settings in which CTLA-4-deficient Treg retain suppressive function in vivo can also be found in the literature [29,33,92] and serve as important reminders that alternative mechanisms can compensate for a lack of CTLA-4 in certain circumstances. Overall, the data point to a key role for CTLA-4 in Treg function although other mechanisms can sometimes substitute in its absence.

4.4. Role for CTLA-4 in the conventional T cell compartment

It has been clearly established that CTLA-4 can also function to regulate T cell responses when expressed on conventional T cells. Ironically, the general acceptance of this idea owes much to the early experiments showing that CTLA-4 antibodies altered T cell proliferation in vitro [100–103] that were performed prior to widespread recognition of the Treg lineage. These experiments were generally performed on whole CD4 T cells, rather than on purified CD4+CD25− cells; with the benefit of hindsight, it is likely that many of the CTLA-4 effects demonstrated in these early studies were actually a result of targeting CTLA-4 on the Treg population. Nevertheless, even when TCR transgenic systems have been used in subsequent studies to rigorously select against the presence of Treg it is clear that CTLA-4 can still function to regulate the magnitude of conventional T cell responses. Extensive evidence supports the function of CTLA-4 in the Tconv compartment [104–111], including the demonstration that CTLA-4 regulates the Tconv response to soluble antigen [104] and to tissue-derived neo-self antigen [105] as well as modulating the capacity of Tconv to infiltrate antigen-bearing tissues and cause destruction [108]. The finding that mice lacking CTLA-4 only in Treg live longer than those lacking CTLA-4 systemically [81] also points to a functional role for CTLA-4 in the conventional T cell population.

5. Overall perspectives

5.1. Why is Treg function CTLA-4-independent in some studies?

The demonstration that loss of CTLA-4 in the Treg compartment is sufficient to precipitate lethal autoimmunity [81] implies that
Table 2

Examples of studies in which CTLA-4 has been shown to contribute to Treg function.

| CTLA-4−/− Treg population tested | Observation | Reference |
|----------------------------------|-------------|-----------|
| CD4+CD25+ cells                 | Regulation of colitis by CTLA-4-sufficient Treg was largely abrogated by anti-CTLA-4 blocking antibody. | [33] |
| Foxp3-expressing cells          | Specific deletion of CTLA-4 in Treg (by expression of Foxp3-driven Cre in CTLA-4-floxed mice) caused lethal T cell mediated autoimmunity featuring lymphadenopathy, splenomegaly and widespread tissue infiltration. | [81] |
| CD4+CD25+ cells                 | DO11.10+ Treg were unable to control autoimmune pancreas destruction in an adoptive transfer model of diabetes. Wildtype Treg bearing an identical specificity (DO11.10+ Treg) conferred 100% protection from disease. | [79] |
| CD4+CD25+ CD62L+ cells (from young CTLA-4−/− mice) | CTLA-4−/− Treg failed to control colitis induced by T cell transfer into rag−/− recipients. Wildtype Treg conferred protection from colitis. | [94] |
| CD4+CD25+ cells                 | Injection of wildtype Treg but not conventional T cells (CD4+CD25−) significantly prolonged the lifespan of CTLA-4−/− mice. | [80] |
| CD4+CD25+ cells                 | Wildtype Treg completely prevented disease induced by CTLA-4−/− T cells in rag−/− recipients, demonstrating that expression of CTLA-4 in Treg is sufficient for regulation, even if conventional T cells lack CTLA-4. | [87] |
| CD4+CD25+ cells                 | Treg from CTLA-4−/− mice expressing CTLA-4 only in activated conventional T cells (under the control of the IL-2 promoter) failed to control colitis induced by CD4+CD25− cells in rag−/− recipients. Wildtype Treg conferred 100% protection. | [109] |
| CD4+CD25+ CD62L+ cells          | CTLA-4−/− but not CTLA-4−/− Treg reduced the infiltration of antigen-specific effector T cells into the pancreas and prevented the destruction of pancreatic tissue. | [108] |
| CD4+CD25+ cells (purified from healthy mixed bone marrow chimeras) | CTLA-4−/− Treg failed to suppress inflammatory bowel disease induced by T cell transfer into rag−/− recipients (0/4 mice survived). Recipients of wildtype Treg showed complete protection (4/4 mice survived). | [88] |

CTLA-4 is of fundamental importance in the Treg lineage. That being so, it prompts the question; why don’t investigators uniformly identify a role for CTLA-4 in Treg function? Although numerous studies report CTLA-4-dependent Treg function (see Table 2), there are notable exceptions where Treg lacking CTLA-4 elicit effective suppression. In my view, there are three main issues to consider in this regard; whether the response being targeted is CD28-dependent, the tissue site and differentiation state of the cells being regulated, and the nature of the Treg itself.

As emphasized earlier, the central biological role of CTLA-4 is to regulate the CD28 pathway (potentially via ligand competition [112] and ligand downregulation [99,113–115] although other mechanisms are also plausible). It follows that T cell responses that do not utilize CD28 costimulation would not be predicted to be subject to CTLA-4-dependent regulation. Interestingly, a recent study using BDC2.5 Treg found that CTLA-4-deficient cells were just as effective as their wildtype counterparts at regulating diabetes in an adoptive transfer model [29]. However, the diabetes model employed was the CD28KO.NOD mouse in which the diabetogenic T cell response is, by definition, CD28-independent. Thus, the failure to demonstrate CTLA-4-dependent immune regulation in this setting is expected, given that competition for (or downregulation of) CD86 and CD80 would not be predicted to alter the activation of CD28-deficient T cells. In contrast, in a different TCR-transgenic diabetes model, CTLA-4 deficiency abrogated the ability of Treg to control disease [79]. The latter model utilized CD28-sufficient mice and the diabetogenic T cell response is CD28-dependent in this system (Wang and Walker, unpublished observation) providing a potential explanation for this difference.

Regarding context of the response being regulated, susceptibility to regulation via non-CTLA-4-based mechanisms may vary depending on the tissue site and differentiation state of the T cells. In the gut, IL-10 production may represent a good alternative to CTLA-4 in controlling errant T cell responses. Accordingly regulation of colitis by wildtype Treg can be blocked by anti-CTLA-4 antibody, but CTLA-4-deficient Treg can instead utilize IL-10 to achieve regulation [33]. In the pancreas, on the other hand, IL-10 may be a less reliable inhibitor of T cell immunity. While IL-10 can inhibit diabetes under certain circumstances [116,117], transgenic expression of IL-10 in the pancreas can actually exacerbate diabetes [118]. Thus, IL-10 produced by CTLA-4-deficient Tregs could conceivably be less effective at eliciting immunosuppression in the pancreas. The stage of the immune response may also dictate the relative efficacy of different suppressive mechanisms since preventing T cell priming and curbing fully-differentiated effectors may be fundamentally different processes.

Regarding the nature of the Treg, there has been much interest in recent years in the subdivision of Treg into subsets based largely on their transcription factor expression [119–123] or anatomical location [124,125]. Frequently the transcriptional profile of a given Treg subset is reported to parallel that of the effector T cell subset targeted for control [126]. While there are other ways to interpret these data [127], at face value the message is that Treg are not a homogenous population. It follows that different subsets of Treg could employ particular suppressive mechanisms to differing extents. The careful characterization of human Treg populations by the Sakaguchi laboratory revealed that those expressing CD45RA produce more TGFβ while the CD45RA-negative subset bear higher CTLA-4 expression and are capable of greater IL-10 production [128]. Thus, the type or differentiation state of the Treg population in question may influence the dominant mechanism of suppression it employs.
5.2. Does CTLA-4 work differently in Treg and Tconv – do CTLA-4-expressing Tconv have regulatory function?

If we accept that CTLA-4 can indeed function in both the Treg and Tconv compartments, one question that arises is how do these functions differ? Early models of CTLA-4 function were based on the notion that this receptor delivers a negative signal [101–103], and certainly many of my own papers were written from this perspective [105,129,130]. However, more recently the concept has emerged that CTLA-4 can function cell-extrinsically, indirectly controlling the responses of T cells that do not in fact express it [13]. This begs the question of whether CTLA-4 functions one way in conventional T cells (for example transducing negative signals to inhibit their activation) and another way in Treg (for example triggering ligand downregulation on antigen presenting cells [99,115]). Recent findings have shed new light on this issue; surprisingly, both the Allison laboratory [110] and my own group [111] found that conventional T cells were able to use CTLA-4 in a cell-extrinsic manner – essentially just like Treg do. Accordingly conventional T cells expressing CTLA-4 were able to regulate the proliferation of CTLA-4-deficient conventional T cells in their midst. Interestingly a microarray comparison of CTLA-4-sufficient and CTLA-4-deficient conventional T cells revealed “no obvious signature of active negative regulation” in the former [110], suggesting that even in conventional T cells, extrinsic mechanisms of CTLA4 function may be more important than the transmission of negative signals.

If CTLA-4 functions the same way in Treg and Tconv, and can direct a cell-extrinsic regulatory program, does this then blur the distinction between Tconv and Treg? In other words, are we now claiming that all T cells are essentially regulatory T cells by virtue of their ability to express CTLA-4? We recently explored this issue by comparing the capacity of CTLA-4-sufficient Tconv and Treg to control the lymphoproliferative disease associated with CTLA-4 deficiency [111]. We took advantage of the fact that disease can be transferred into rag-/- recipients by injecting peripheral lymphocytes from CTLA-4+/+ animals [131]. We found that even though co-transferred Tconv could express CTLA-4, they were unable to prevent disease, with the recipient animals losing as much weight as those receiving CTLA-4-/- cells alone. In contrast co-transferred Treg were highly effective at preventing disease and the recipient animals did not lose weight. This disease model is particularly aggressive, not least because the peripheral CTLA-4-/- lymphocytes are already activated at the point of adoptive transfer. To probe a little deeper we adapted the system by adoptively transferring CTLA-4-/- bone marrow rather than peripheral lymphocytes. This invokes a slower, less severe disease in the rag-/- recipients that we reasoned might be easier to control. Accordingly, adoptively transferred CTLA-4-sufficient Tconv were able to partially regulate disease in this setting leading to reduced weight loss, less severe tissue infiltration and decreased activation of peripheral T cells [111]. While this showed that Tconv-expressed CTLA-4 could partially regulate disease, it should be emphasized that regulation was modest compared to that invoked by CTLA-4-sufficient Treg. Recipients of the latter showed no weight loss (and instead gained weight), they lacked tissue infiltration and control of peripheral T cell activation was far more profound. Taken together, the overriding message is that although CTLA-4-sufficient Tconv exhibit modest suppressive capacity, Treg are far superior at eliciting regulation. This likely reflects their higher level of CTLA-4 expression and the fact that they express CTLA-4 constitutively, unlike Tconv that require a 2 day window to upregulate this protein [100,101,132]. Furthermore, the concomitant production of cytokines by conventional T cells, that are silenced in Treg by Foxp3, may serve to counteract suppression. Interestingly forced expression of CTLA-4 in activated T cells under the IL-2 promoter was able to significantly delay disease in CTLA-4-deficient mice [109]. Since IL-2 is induced rapidly upon T cell activation [133] early CTLA-4 induction may explain the superior capacity of these T cells to control disease, compared with Tconv that naturally express CTLA-4 in mice selectively lacking CTLA-4 in Treg [81]. The notion that Treg are the dominant population eliciting CTLA-4-dependent regulation, and that CTLA-4 function in Tconv plays a supplementary role, may explain the lack of complementation between scurfy and CTLA-4-/- bone marrow [82] since Treg may need to be present for the CTLA-4 effects on Tconv to be revealed.

6. Conclusion

Although the CTLA-4 and Foxp3 stories emerged independently of one another, they are nonetheless inextricably entwined (see Fig. 2). A large portion of CTLA-4-dependent immune regulation is achieved via expression of this molecule in the Treg compartment. Conversely Treg rely heavily, although by no means exclusively, on CTLA-4 to elicit regulatory function. Appreciation of the significant functional overlap between Foxp3 and CTLA-4 driven regulatory programs, and recognition of the cases where these pathways diverge, will guide the future harnessing of these pathways in therapeutic settings.

7. Final comments

This review was written to honor Professor Abul Abbas who has been a valued mentor and friend to me for over a decade. It is part of an issue which is devoted to Professor Abul Abbas and part of the Journal of Autoimmunity’s recognition of truly distinguished immunologists who have contributed so much to our field; previous honorees have included Harry Moutsopoulos, Ian Mackay, Noel Rose, Chella David and Pierre Youinou [134–136]. My initial studies into both CTLA-4 and regulatory T cells emanated form work carried out in Abul’s lab where I remember with great fondness my time as a Wellcome Trust postdoctoral fellow. His warmth, openness and generosity and excitement over new data are things I recall vividly. Abul’s ability to convey the essence of a seminar in a single sentence and his unwavering grasp on the “big picture” are things I will always admire. It’s a pleasure to be able to offer this
Acknowledgments

I am grateful to D. Sansom and B. Seddon for helpful comments on the manuscript. LS.KW is funded by an MRC Non-Clinical Senior Fellowship.

References

[1] Walker LS, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol 2002;2(1):11–9.

[2] Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmune throughout the lifespan of mice. Nat Immunol 2007;8(2):191–7.

[3] Tivol EA, Borrelli F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of ctla-4 leads to massive lymphoproliferation and fatal multorgan tissue destruction, revealing a critical negative regulatory role of ctla-4. Immunity 1995;3(5):541–7.

[4] Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in ctla-4. Science 1995;270(5288):585–8.

[5] Linsley PS, Bradshaw J, Greeve B, et al. Traf1 and 2: the emerging role of ctla4 and tlr4 as cell-extrinsic regulators. J Immunol 2005;175(2):687–93.

[6] Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Rudd CE, Taylor A, Schneider H. CD28 and ctla-4 coreceptor expression and signal transduction. Immunol Rev 2009;229(1):12–7.

[7] Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. Ctla-4: a negative signal transduction molecule that controls T cell activation. J Immunol 2001;166(1):277–30.

[8] Luhder F, Chambers C, Allison JP, Benoist C, Mathis D. Ctla-4 regulates the unfolding of autoimmune diabetes. J Exp Med 2000;192(2):303–11.

[9] Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Abnormal t cell reactivity against paternal antigens in spontaneous type 1 diabetes region in non-obese diabetic mice. J Immunol 2009;183(8):5146–57.

[10] Gozalo-Sanmillan S, McNally JM, Lin MY, Chambers CA, Berg LJ. Cutting edge: two distinct mechanisms lead to impaired T cell homeostasis in janus kinase 3- and ctla-4-deficient mice. J Immunol 2001;166(2):277–30.

[11] Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in ctla-4-deficient mice is mediated by lymphoproliferation-dependent activation of cd4+ cells. Immunol 1997;7:885–95.

[12] Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. Ctla-4: a negative signal transduction molecule that controls T cell activation. J Exp Med 2000;192(2):303–11.

[13] Luhder F, Chambers C, Allison JP, Benoist C, Mathis D. Ctla-4 regulates the unfolding of autoimmune diabetes. J Exp Med 1998;188(2):287–96.

[14] Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. Ctla-4: a negative signal transduction molecule that controls T cell activation. J Exp Med 2000;192(2):303–11.

[15] Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Abnormal t cell reactivity against paternal antigens in spontaneous type 1 diabetes region in non-obese diabetic mice. J Immunol 2009;183(8):5146–57.

[16] Gozalo-Sanmillan S, McNally JM, Lin MY, Chambers CA, Berg LJ. Cutting edge: two distinct mechanisms lead to impaired T cell homeostasis in janus kinase 3- and ctla-4-deficient mice. J Immunol 2001;166(2):277–30.

[17] Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. Ctla-4: a negative signal transduction molecule that controls T cell activation. J Exp Med 2000;192(2):303–11.

[18] Luhder F, Chambers C, Allison JP, Benoist C, Mathis D. Ctla-4 regulates the unfolding of autoimmune diabetes. J Exp Med 2000;192(2):303–11.

[19] Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Abnormal t cell reactivity against paternal antigens in spontaneous type 1 diabetes region in non-obese diabetic mice. J Immunol 2009;183(8):5146–57.

[20] Gozalo-Sanmillan S, McNally JM, Lin MY, Chambers CA, Berg LJ. Cutting edge: two distinct mechanisms lead to impaired T cell homeostasis in janus kinase 3- and ctla-4-deficient mice. J Immunol 2001;166(2):277–30.

[21] Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Abnormal t cell reactivity against paternal antigens in spontaneous type 1 diabetes region in non-obese diabetic mice. J Immunol 2009;183(8):5146–57.

[22] Gozalo-Sanmillan S, McNally JM, Lin MY, Chambers CA, Berg LJ. Cutting edge: two distinct mechanisms lead to impaired T cell homeostasis in janus kinase 3- and ctla-4-deficient mice. J Immunol 2001;166(2):277–30.

[23] Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Abnormal t cell reactivity against paternal antigens in spontaneous type 1 diabetes region in non-obese diabetic mice. J Immunol 2009;183(8):5146–57.

[24] Gozalo-Sanmillan S, McNally JM, Lin MY, Chambers CA, Berg LJ. Cutting edge: two distinct mechanisms lead to impaired T cell homeostasis in janus kinase 3- and ctla-4-deficient mice. J Immunol 2001;166(2):277–30.

[25] Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Abnormal t cell reactivity against paternal antigens in spontaneous type 1 diabetes region in non-obese diabetic mice. J Immunol 2009;183(8):5146–57.

[26] Gozalo-Sanmillan S, McNally JM, Lin MY, Chambers CA, Berg LJ. Cutting edge: two distinct mechanisms lead to impaired T cell homeostasis in janus kinase 3- and ctla-4-deficient mice. J Immunol 2001;166(2):277–30.

[27] Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Abnormal t cell reactivity against paternal antigens in spontaneous type 1 diabetes region in non-obese diabetic mice. J Immunol 2009;183(8):5146–57.
Godfrey VL, Wilkinson JE, Russell LB. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol 1991;138(6):1379–87.

Hori S, Nomura M, Sakaguchi S. Control of regulatory T cell development by the transcription factor foxp3. Science 2003;299(5609):1057–61.

Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of cd4(+) cd25(+) regulatory T cells. Nat Immunol 2003;4(4):330–6.

Wildin RS, Gavin MA, Peake VJ, Casanova JL, Peake J, Faravelli F, et al. X-linked lymphoreticular disease in the absence of the transcription factor foxp3. Nature 2001;271(1):18–20.

Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of foxp3 target genes in developing and mature regulatory T cells. Immunity 2007;26(2):152–62.

Waller LS, Chodos A, Eggena M, Dooms H, Abbas AK. Antigen-dependent control of cd4(+) cd25(+) regulatory T cells in vivo. J Exp Med 2003;198(2):249–58.

Lathrop SK, McHaffie NA, Pham D, Luo J, Hsieh CS. Antigen-specific peripheral shaping of the normal regulatory T cell population. J Exp Med 2008;205(13):3105–17.

Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of foxp3 target genes in developing and mature regulatory T cell development. Nature 2001;409(6822):694–701.

Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, MacSaic KD, et al. Foxp3 occupation and regulatory function of key target genes during T-cell stimulation. Nature 2007;445(7130):936–41.

Rudra D, deRoos P, Chaudhry A, Niec RE, Arvey A, Samstein RM, et al. Foxp3 expression and its protein partners form a complex regulatory network. Nat Immunol 2012;13(10):1010–9.

Wu Y, Börde M, Heissmann V, Feuerer M, Lapan AD, Stroud JC, et al. Foxp3 controls regulatory T cell function through cooperation with nft. Cell 2006;126(2):375–87.

Ono M, Yagiuchi H, Okuhira N, Kitabatashi I, Nagamura Y, Nomura T, et al. Foxp3 controls regulatory T-cell function by interacting with anil1/runnx1. J Exp Med 2007;204(5):665–9.

Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT, et al. Regulatory T-cell suppressor program co-opts transcription factor irf4 to control t(h)2 regulatory T cells. Immunity 2007;26(2):152–62.

Allen SE, Passier I, Barchetta R, Cirelli N, Dairi M, Orban PC, et al. The role of 2 foxp3 isoforms in the generation of human cd4(+) treg. J Clin Invest 2005;115(5):1236–44.

Zheng Y, Manzotti CN, Burke F, Duss下跌 L, Qureshi O, Walker LS, et al. Acquisition of suppressive function by activated human cd4(+) cd25(+) T cells is associated with the expression of cd4(+) not foxp3. J Immunol 2008;181(1):1683–91.

Fu W, Ergun A, Lu T, Hill JA, Haixinostos S, Fassett MS, et al. A multiply redundant genetic switch ‘locks’ in the transcriptional signature of regulatory T cells. Nat Immunol 2012;13(10):972–80.

Chuang H, Martin S, Pfleger C, Du J, Buckner JH, Bluestone JA, et al. Cutting edge: a novel, human-specific interacting protein complex couples foxp3 to a chromosome-remodeling complex that contains kap1/trim28. J Immunol 2013;190(9):4470–3.

Metzler B, Burkhart C, DTC. Phenotypic analysis of cd4(+) and cd28 expression during transient peptide-induced T cell activation in vivo. Int Immunol 1999;11(5):685–77.

Schmitz EM, Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. Cooperative roles of ctla-4 and regulatory T cells in tolerance to an islet cell immunogen. J Immunol 2002;169(11):6202–9.

Jain N, Nguyen H, Chambers C, Kang J. Dual function of ctla-4 on effector T cells. J Exp Med 2004;199(4):1725–30.

Pegg KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of ctla-4 increases the persistence and suppressor function of regulatory T cells in vivo. J Immunol 2010;185(1):253–40.

Walunas TL, Bakker CY, Bluestone JA. CD4+ ligation blocks cd4+28-dependent T cell activation. J Exp Med 1996;183:2541–50.

Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. CD4+ T cells regulate induction of energy in vivo. J Exp Med 2001;193(11):1285–9.

Walker LS, Ausubel LJ, Chodos A, Bekarian N, Abbas AK. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of cd4(+) cd25(+) regulatory T cells that control intestinal inflammation. J Exp Med 2000;192(2):295–302.

Peeters NA, Zilberstein D, Rosegger B, Burkhart C, Wraith DC. Phenotypic analysis of ctla-4 and cd28 expression in peripheral blood regulatory T cells. J Immunol 2003;171(10):6876–84.

Wallon H, Dummer W, Wolle T, Rodrigo E, Theofilopoulos AN, Oldstone MB, et al. Lack of intrinsic ctla-4 expression has minimal effect on regulation of antiviral T-cell immunity. J Virol 2006;80(1):270–80.

Chen H, Wang J, Krieger A, Kehrl JH, Younkin LH, Yewdell JW, et al. Cooperative roles of cd4(+) and ctla-4 in the maintenance of systemic tolerance. J Exp Med 2002;196(3):421–7.

Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 is associated with the expression of ctla-4 not foxp3. J Immunol 2008;181(3):1675–83.

Chen JF, Romanski J, Meeker MK, Brown MM, Krieger A, Younkin LH, et al. Cooperative roles of cd4(+) and ctla-4 in the maintenance of systemic tolerance. J Exp Med 2002;196(3):421–7.

Chikuma S, Bluestone JA. Expression of cd4(+) and foxp3 in cis protects from lethal lymphoproliferative disease. Eur J Immunol 2007;37(5):1285–9.

Ouyang W, Becker T, Du Q, Pal JH, Dwyer RA, LU MI. Foxo transcription factors cooperatively control the differentiation of foxp3+ regulatory T cells. Nat Immunol 2010;11(7):618–27.

Komatsu N, Hori S. Full restoration of peripheral foxp3+ regulatory T cell pool by restoring Foxo3a, a unique bone marrow chimera. Proc Natl Acad Sci U S A 2007;104(21):8959–64.

Bachmann MF, Kohler G, Ecbert B, Mak TW, Kopf M. Cutting edge: lymphoproliferative disease in the absence of cd4(+) is not T cell autonomous. J Immunol 1999;163(8):4181–5.

Homann D, Dummer W, Wolfe T, Rodrigo E, Theofilopoulos AN, Oldstone MB, et al. Lack of intrinsic ctla-4 expression has minimal effect on regulation of antiviral T-cell immunity. J Virol 2006;80(1):270–80.

Friedman BH, Brown MM, Krieger A, Zheng Y, et al. CD4+ regulatory T cells require ctla-4 for the maintenance of systemic tolerance. J Exp Med 2009;206(2):421–41.

Tai X, Van Laethem F, Pobezinsky L, Guenter T, Sharrow SO, Adams A, et al. Basis of ctla-4 function in regulatory and conventional cd4(+) T cells. Blood 2012;119(22):5155–63.

Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of cd4(+) cd25(+) regulatory T cells that control intestinal inflammation. J Exp Med 2000;192(2):295–302.

Chen JF, Romanski J, Meeker MK, Brown MM, Krieger A, Younkin LH, et al. Cooperative roles of cd4(+) and ctla-4 in the maintenance of systemic tolerance. J Exp Med 2002;196(3):421–7.

Chikuma S, Bluestone JA. Expression of cd4(+) and foxp3 in cis protects from lethal lymphoproliferative disease. Eur J Immunol 2007;37(5):1285–9.

Ouyang W, Becker T, Du Q, Pal JH, Dwyer RA, LU MI. Foxo transcription factors cooperatively control the differentiation of foxp3+ regulatory T cells. Nat Immunol 2010;11(7):618–27.

Komatsu N, Hori S. Full restoration of peripheral foxp3+ regulatory T cell pool by restoring Foxo3a, a unique bone marrow chimera. Proc Natl Acad Sci U S A 2007;104(21):8959–64.

Bachmann MF, Kohler G, Ecbert B, Mak TW, Kopf M. Cutting edge: lymphoproliferative disease in the absence of cd4(+) is not T cell autonomous. J Immunol 1999;163(8):4181–5.
